Fig. 3.
Fig. 3. Demonstration of telomerase positivity when previously telomerase-negative HD samples with eosinophilia were reanalyzed using RNase protection. All samples were analyzed with 10 U/μL placental RNase inhibitor present. Lanes 1 and 4, negative (lysis buffer) and positive control (1301 cell line, 0.14 μg/assay), respectively. Lanes 2 and 3, sample A analyzed at 0.56 and 0.28 μg/assay, respectively. Lanes 5, 6, and 7, sample B analyzed at 0.14, 0.28, and 0.56 μg/assay, respectively. Lanes 8, 9, and 10, sample C analyzed at 0.14, 0.28, and 0.56 μg/assay, respectively. The amplification of ITAS in sample A was not decreased, indicating that no free, unbound RNases were present in the extract and supporting the idea that the sample was truly telomerase-negative.

Demonstration of telomerase positivity when previously telomerase-negative HD samples with eosinophilia were reanalyzed using RNase protection. All samples were analyzed with 10 U/μL placental RNase inhibitor present. Lanes 1 and 4, negative (lysis buffer) and positive control (1301 cell line, 0.14 μg/assay), respectively. Lanes 2 and 3, sample A analyzed at 0.56 and 0.28 μg/assay, respectively. Lanes 5, 6, and 7, sample B analyzed at 0.14, 0.28, and 0.56 μg/assay, respectively. Lanes 8, 9, and 10, sample C analyzed at 0.14, 0.28, and 0.56 μg/assay, respectively. The amplification of ITAS in sample A was not decreased, indicating that no free, unbound RNases were present in the extract and supporting the idea that the sample was truly telomerase-negative.

Close Modal

or Create an Account

Close Modal
Close Modal